Latest

3 stories

Hide weekly roundups

Thursday, September 24

Legend Biotech shareholders back directors, auditor, and share plan increase at 2026 AGM

At its September 24, 2026 annual meeting, Legend Biotech investors re-elected four directors and approved adding 19.1 million shares to its restricted share plan.

SEC filing

Tuesday, September 15

PeopleLegend Biotech Corp

Legend Biotech names Ingrid Zhang CEO, effective September 15, 2026

Zhang, formerly Novartis International's Chief Commercial Officer, succeeds interim CEO Alan Bash, who returns to lead the CARVYKTI business.

SEC filing

Tuesday, August 18

PeopleLegend Biotech Corp

Legend Biotech seeks shareholder approval to add 19.1 million shares to RSU plan

The proxy for Legend Biotech's September 24, 2026 annual meeting asks holders to expand the equity plan and re-elect four Class III directors.

SEC filing